Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Status: Recruiting
Location: See all (26) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Migraine diagnosis according to ICHD-III.
• Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
• Signature of informed consent.
Locations
United States
Florida
University of Miami, Miller School of Medicine
RECRUITING
Miami
Other Locations
Argentina
FLENI
RECRUITING
Buenos Aires
Chile
Pontificia Universidad Católica de Chile
RECRUITING
Santiago
Colombia
Neuromedica
RECRUITING
Medellín
Croatia
Special Hospital for Orthopedics and Rehabilitation Martin Horvat Rovinj-Rovigno
RECRUITING
Rovinj
Germany
Charité Universitätsmedizin Berlin
RECRUITING
Berlin
LMU University Hospital
RECRUITING
München
Italy
University of L'Aquila
RECRUITING
L’aquila
University of Modena and Reggio Emilia
RECRUITING
Modena
National Neurological Institute C. Mondino Foundation
RECRUITING
Pavia
IRCCS San Raffaele
RECRUITING
Roma
Malaysia
Universiti Putra Malaysia
RECRUITING
Serdang
Norway
Neuroclinic Norway
RECRUITING
Lillestrøm
Poland
Wrocław Medical University
RECRUITING
Wroclaw
Portugal
Hospital Santa Maria Lisbon
RECRUITING
Lisbon
Spain
Hospital General Universitario de Albacete
RECRUITING
Albacete
Germans Trias i Pujol Hospital
RECRUITING
Badalona
Vall d'Hebron University Hospital
RECRUITING
Barcelona
Hospital Universitari de Bellvitge
RECRUITING
L'hospitalet De Llobregat
Fundación Jiménez Díaz
RECRUITING
Madrid
Hospital Universitario Gregorio Marañón
RECRUITING
Madrid
La Paz University Hospital
RECRUITING
Madrid
Fundació Sanitària Mollet
NOT_YET_RECRUITING
Mollet Del Vallès
Hospital de Viladecans
RECRUITING
Viladecans
Hospital Clínico Universitario Lozano Blesa
RECRUITING
Zaragoza
Turkey
Mersin University
RECRUITING
Mersin
Contact Information
Primary
Patricia Pozo-Rosich, MD, PhD
cefalea@vhir.org
(+34) 93 489 30 00
Backup
Edoardo Caronna, MD, PhD
cefalea@vhir.org
(+34) 93 489 30 00
Time Frame
Start Date: 2024-01-02
Estimated Completion Date: 2026-01
Participants
Target number of participants: 700
Treatments
Migraine Patients
Migraine patients who initiate a CGRP-targeted treatment
Sponsors
Leads: Hospital Universitari Vall d'Hebron Research Institute